^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD28 agonist

    Related drugs:
    11d
    A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=300, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    ubamatamab (REGN4018) • Kevzara (sarilumab)
    15d
    RNDO-564-001: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 (clinicaltrials.gov)
    P1, N=149, Enrolling by invitation, Rondo Therapeutics | Recruiting --> Enrolling by invitation
    Enrollment status
    |
    Keytruda (pembrolizumab)
    1m
    A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, Regeneron Pharmaceuticals
    New P1/2 trial • First-in-human
    |
    Lynozyfic (linvoseltamab-gcpt)
    1m
    Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Recruiting, ModeX Therapeutics, An OPKO Health Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    2ms
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC (clinicaltrials.gov)
    P1, N=138, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    2ms
    A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=250, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2027 --> Jun 2028
    Trial completion date
    |
    pasritamig (JNJ-8343)
    2ms
    COMBINE-EGFR-1: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (clinicaltrials.gov)
    P1/2, N=933, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Dec 2026 --> Apr 2027
    Trial completion date
    |
    Avastin (bevacizumab) • Libtayo (cemiplimab-rwlc) • Lonsurf (trifluridine/tipiracil)
    3ms
    MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors. (PubMed, Future Oncol)
    Here, we present the protocol design for study MDX-2001-101, a multicenter, open-label, phase I/IIa clinical trial designed to evaluate the safety, tolerability, and antitumor effects of MDX2001 in patients with advanced solid tumors. The study comprises a phase Ia dose escalation guided by a Bayesian optimal interval design with a targeted maximum tolerated dose toxicity rate of 30%, a phase Ib dose expansion, and a phase IIa indication expansion.
    P1/2 data • Journal • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    3ms
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=235 --> 70 | Trial completion date: Nov 2027 --> Aug 2026 | Trial primary completion date: Nov 2027 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    4ms
    Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial
    |
    capecitabine • oxaliplatin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    4ms
    Study of ZGGS34 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=400, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    alveltamig (ZG006)
    4ms
    This Study is Designed to Characterize the Safety, Tolerability, and Anti-tumor Activity of MDX2003 in Patients With Different Types of Lymphoma (clinicaltrials.gov)
    P1/2, N=180, Not yet recruiting, ModeX Therapeutics, An OPKO Health Company
    New P1/2 trial